FDA moves new breast and colorectal cancer therapies forward, while experts spotlight pancreatic precision drugs and belzutifan safety in ccRCC.
February 2026 Targeted Pulse
Explore this week’s oncology breakthroughs: genomic-driven lung cancer care, record survival gains, and FDA moves in myeloma and subcutaneous amivantamab.
ASCO GU 2026 previews and FDA rulings spotlight new targeted options in bladder, lung, breast, and colorectal cancers.